CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project develops innovative lipid-based drug delivery systems that enhance the targeting and effectiveness of therapeutic agents for diseased cells. By addressing the limitations of current methods, such as PEGylation, it aims to improve cellular uptake and therapeutic efficiency in nanomedicine applications.
Delivery to diseased cells or tissues of therapeutic agents attached or encapsulated in nanoparticles – nanomedicine - presents many benefits, and comprises a rapidly-growing multi-billion-euro market.
Lipid-based drug-delivery nano-vehicles, where drugs (not least the recent, very-widely-used, mRNA-based COVID-19 vaccines) are encapsulated in lipid vesicles (liposomes) or lipid nanoparticles, form a substantial part of that market.
Nearly all FDA-approved liposomic vehicles are functionalized w…
WEIZMANN INSTITUTE OF SCIENCE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
